Literature DB >> 24967195

Comparison of the efficacies of patching and penalization therapies for the treatment of amblyopia patients.

Cemalettin Cabi1, Isil Bahar Sayman Muslubas2, Ayse Yesim Aydin Oral3, Metin Dastan4.   

Abstract

AIM: To compare the efficacies of patching and penalization therapies for the treatment of amblyopia patients.
METHODS: The records of 64 eyes of 50 patients 7 to 16y of age who had presented to our clinics with a diagnosis of amblyopia, were evaluated retrospectively. Forty eyes of 26 patients who had received patching therapy and 24 eyes of 24 patients who had received penalization therapy included in this study. The latencies and amplitudes of visual evoked potential (VEP) records and best corrected visual acuities (BCVA) of these two groups were compared before and six months after the treatment.
RESULTS: In both patching and the penalization groups, the visual acuities increased significantly following the treatments (P<0.05). The latency measurements of the P100 wave obtained at 1.0°, 15 arc min. Patterns of both groups significantly decreased following the 6-months-treatment. However, the amplitude measurements increased (P<0.05).
CONCLUSION: The patching and the penalization methods, which are the main methods used in the treatment of amblyopia, were also effective over the age of 7y, which has been accepted as the critical age for the treatment of amblyopia.

Entities:  

Keywords:  amblyopia; patching therapies; penalization therapies; visual evoked potential

Year:  2014        PMID: 24967195      PMCID: PMC4067663          DOI: 10.3980/j.issn.2222-3959.2014.03.17

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  18 in total

1.  ISCEV standard for clinical visual evoked potentials (2009 update).

Authors:  J Vernon Odom; Michael Bach; Mitchell Brigell; Graham E Holder; Daphne L McCulloch; Alma Patrizia Tormene
Journal:  Doc Ophthalmol       Date:  2009-10-14       Impact factor: 2.379

Review 2.  Critical periods and amblyopia.

Authors:  N W Daw
Journal:  Arch Ophthalmol       Date:  1998-04

3.  1999 Costenbader Lecture. Outcome study in amblyopia: treatment and practice pattern variations.

Authors:  M L Mazow; A Chuang; M C Vital; T Prager
Journal:  J AAPOS       Date:  2000-02       Impact factor: 1.220

4.  A randomized trial of atropine regimens for treatment of moderate amblyopia in children.

Authors:  Michael X Repka; Susan A Cotter; Roy W Beck; Raymond T Kraker; Eileen E Birch; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Nicholas A Sala; Mitchell M Scheiman; David R Stager; David K Wallace
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

5.  A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children.

Authors:  Jonathan M Holmes; Raymond T Kraker; Roy W Beck; Eileen E Birch; Susan A Cotter; Donald F Everett; Richard W Hertle; Graham E Quinn; Michael X Repka; Mitchell M Scheiman; David K Wallace
Journal:  Ophthalmology       Date:  2003-11       Impact factor: 12.079

6.  Refractory reverse amblyopia with atropine penalization.

Authors:  Preeti Ajit Patil; S Meenakshi; T S Surendran
Journal:  Oman J Ophthalmol       Date:  2010-09

7.  Treatment of children with amblyopia by perceptual learning.

Authors:  Uri Polat; Tova Ma-Naim; Abraham Spierer
Journal:  Vision Res       Date:  2009-07-19       Impact factor: 1.886

8.  Amblyopia treatment outcomes after screening before or at age 3 years: follow up from randomised trial.

Authors:  C Williams; K Northstone; R A Harrad; J M Sparrow; I Harvey
Journal:  BMJ       Date:  2002-06-29

9.  Treatment dose-response in amblyopia therapy: the Monitored Occlusion Treatment of Amblyopia Study (MOTAS).

Authors:  Catherine E Stewart; Merrick J Moseley; David A Stephens; Alistair R Fielder
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

Review 10.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Kate Shotton
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.